RecruitingNot ApplicableNCT05230784

The PURI-HF (Air Purifiers on Heart Failure) Trial

Effectiveness of Indoor Air Purifiers on Heart Failure Outcomes

Sponsor

NYU Langone Health

Enrollment

255 participants

Start Date

Mar 6, 2024

Study Type

INTERVENTIONAL

Conditions

Heart Failure

Summary

Indoor air pollution and fine mode particulate matter with an aerodynamic diameter smaller than 2.5 micrometers (PM2.5) is a major contributor to global morbidity and mortality, particularly due to cardiovascular disease. This project aims to demonstrate the efficacy, feasibility and effectiveness of portable air filters in improving indoor PM2.5 levels and improving functional capacity of heart failure patients with reduced ejection fraction in India. The findings from the project will add to existing knowledge of innovative and scalable strategies to improve environmental and cardiovascular health worldwide. The overall objective of this study is to demonstrate the efficacy, feasibility, and effectiveness of portable air filters in improving indoor PM2.5 levels and improving functional capacity of heart failure patients with reduced ejection fraction in India.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial (PURI-HF) is testing whether placing air purifiers in the homes of heart failure patients can improve their exercise capacity and quality of life by reducing their exposure to indoor air pollution and particulate matter. **You may be eligible if...** - You are 18 or older - You have been diagnosed with heart failure with a reduced ejection fraction (40% or less) within the last 6 months - Your heart failure symptoms are in the moderate-to-severe range (NYHA Class II–IV) **You may NOT be eligible if...** - You are on the heart transplant waiting list - You have had a cardiac resynchronization therapy device implanted in the past 3 months - You are currently on supplemental oxygen therapy - You have severe lung disease - You cannot walk independently Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERAirOk Air Purifier

The AirOk purifier nests on a locally developed patented technology that combines HEPA (grade H12) and a novel EGAPA (Effective Granular Adsorbent Particulate Arrestor) to reduce indoor air pollution. The HEPA filter removes all particulate matter up to 0.3 µm in aerodynamic diameter, and the dual stratified EGAPA filter removes other pollutants such as sulfur, nitrous oxide, carbon oxide, volatile organic compounds, allergens, and mold.

OTHERPlacebo Air Filter

Participants in the placebo arm will receive an air purifier with only the EGAPA filter.